SCHEMBL19836479

SCHEMBL19836479

CC(C)Nc1cc(Br)cnc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.50
HTT P42858 3/20 0.50
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 5/20 0.38
DYRK1A Q13627 2/20 0.37
IDO1 P14902 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 2/20 0.37
MET P08581 1/20 0.36
POLB P06746 2/20 0.35
AOC1 P19801 2/20 0.35
AOC3 Q16853 2/20 0.35
MAPT P10636 2/20 0.35
RAB9A P51151 1/20 0.35
BLM P54132 1/20 0.35
LDHA P00338 1/20 0.35
LDHB P07195 1/20 0.35
KDM4E B2RXH2 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28609306 0.81 KMT2A (0.40) KMT2AHTTNPC1ALDH1A1MEN1
SCHEMBL3772683 0.80 KMT2A (0.46) KMT2AHTTNPC1ALDH1A1MEN1
SCHEMBL29705465 0.80 KMT2A (0.54) KMT2AHTTNPC1ALDH1A1MEN1
SCHEMBL12722223 0.80 KMT2A (0.54) KMT2AHTTNPC1ALDH1A1MEN1
SCHEMBL22011055 0.80 LDHA (0.39) KMT2AHTTNPC1ALDH1A1MEN1
SCHEMBL1621716 0.79 KAT2B (0.37) KMT2AHTTNPC1MEN1SMN1; SMN2
SCHEMBL3644982 0.79 PIK3CD (0.34) KMT2AHTTMEN1SMN1; SMN2LMNA
SCHEMBL1621193 0.78 HTT (0.38) KMT2AHTTNPC1ALDH1A1SMN1; SMN2
SCHEMBL3515224 0.77 LMNA (0.34) HTTNPC1SMN1; SMN2LMNAAOC1
SCHEMBL789781 0.76 HTT (0.42) KMT2AHTTNPC1ALDH1A1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415816-B1 PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A BIOSPLICE THERAPEUTICS INC (US) 2026-03-18 EP disclosed
EP-4611890-A1 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BioSplice Therapeutics, Inc. (US) 2025-09-10 EP disclosed
US-12378232-B2 Cyclin dependent kinase inhibitors PFIZER INC. (US) 2025-08-05 US disclosed
US-20250171466-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-05-29 US disclosed
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-04-24 US disclosed
CN-119604506-A 4-Alkoxypyrrolo [2,1-f ] [1,2,4] triazines, preparation and use thereof 拜斯丽治疗有限公司 2025-03-11 CN disclosed
EP-3784664-B1 2-AMINO-PYRIDINE OR 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS PFIZER (US) 2025-02-19 EP disclosed
US-12134625-B2 Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof BIOSPLICE THERAPEUTICS, INC. (US) 2024-11-05 US disclosed
EP-4415816-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A BioSplice Therapeutics, Inc. (US) 2024-08-21 EP disclosed
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 EP disclosed
EP-3784664-A1 2-AMINO-PYRIDINE OR 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS Pfizer Inc. (US) 2021-03-03 EP disclosed
US-20200354350-A1 CYCLIN DEPENDENT KINASE INHIBITORS PFIZER INC. (US) 2020-11-12 US disclosed
US-20200354350-A1 CYCLIN DEPENDENT KINASE INHIBITORS PFIZER INC. (US) 2020-11-12 US disclosed
US-10766884-B2 Cyclin dependent kinase inhibitors PFIZER INC. (US) 2020-09-08 US disclosed
WO-2020151742-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY SHENZHEN TARGETRX, INC. (CN) 2020-07-30 WO disclosed
US-20190330196-A1 CYCLIN DEPENDENT KINASE INHIBITORS PFIZER INC. (US) 2019-10-31 US disclosed
EP-3492462-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY Shenzhen Targetrx, Inc. (CN) 2019-06-05 EP disclosed
EP-3492462-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY Shenzhen Targetrx, Inc. (CN) 2019-06-05 EP disclosed
US-20190152954-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY SHENZHEN TARGETRX, INC. (CN) 2019-05-23 US disclosed
WO-2018019204-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY 深圳市塔吉瑞生物医药有限公司 2018-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10766884-B2 Cyclin dependent kinase inhibitors CCNY, CCNI, CCNK KMT2A 758/4885HTT 3590/4885NPC1 4206/4885
US-20200354350-A1 CYCLIN DEPENDENT KINASE INHIBITORS CCNY, CCNI, CCNK KMT2A 758/4885HTT 3590/4885NPC1 4206/4885
US-12378232-B2 Cyclin dependent kinase inhibitors CCNY, CCNI, CCNK KMT2A 758/4885HTT 3590/4885NPC1 4206/4885
US-20190152954-A1 AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY LCK, WEE1, JAK1 KMT2A 1673/4885HTT 3290/4885NPC1 3516/4885
US-20190330196-A1 CYCLIN DEPENDENT KINASE INHIBITORS CCNY, CCNI, CCNK KMT2A 758/4885HTT 3590/4885NPC1 4206/4885
US-20250171466-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK2, DYRK1B KMT2A 1227/4885HTT 298/4885NPC1 4167/4885
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 KMT2A 1605/4885HTT 608/4885NPC1 3762/4885
US-12134625-B2 Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof DYRK1A, DYRK2, DYRK1B KMT2A 1227/4885HTT 298/4885NPC1 4167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.